Granted Patent
B2
US 12,583,918 · App. 17/601,831 · Granted Mar 24, 2026
Therapeutic agent for urological cancer which is characterized by being administered with IL-6 inhibitor and CCR2 inhibitor in combination
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Therapeutic agents and treatment methods for urologic cancers, particularly urologic cancers with reduced lysine (K)-specific demethylase 6A (KDM6A) function, the agents and methods being characterized by suppressing both IL-6 activity and CCR2/CCL2 activity, are provided.
Claims (15)
1 . A method for treating bladder cancer in a bladder of an individual, the method comprising administering to the individual an anti-IL-6 receptor antibody and propagermanium,
wherein the individual's bladder cancer has one or more of: lysine (K)-specific demethylase 6A (KDM6A) function deficiency, inactivation of KDM6A, and absence of KDM6A protein expression.
2 . The method of claim 1 , wherein the individual is a human and the anti-IL-6 receptor antibody is a chimeric antibody, a humanized antibody, or a human antibody.
3 . The method of claim 1 , wherein cells of the bladder cancer comprise a mutated KDM6A gene.
4 . The method of claim 3 , wherein the mutated KDM6A gene comprises a loss-of-function mutation.
5 . The method of claim 1 , wherein the bladder cancer additionally has one or more of: p53 function deficiency, inactivation of p53, and no detectable p53 protein expression.
6 . The method of claim 1 , wherein cells of the bladder cancer comprise a p53 gene comprising a mutation.
7 . The method of claim 1 , wherein the method reduces growth of bladder cancer cells within a bladder, compared to growth of bladder cancer cells in a bladder in the absence of treatment.
8 . The method of claim 1 , further comprising determining that the individual's bladder cancer has one or more of: KDM6A function deficiency, inactivation of KDM6A, and absence of KDM6A protein expression.
9 . A method for inhibiting growth of a bladder tumor in a bladder of an individual, the method comprising administering to the individual an anti-IL-6 receptor antibody and propagermanium,
wherein the individual's bladder tumor has one or more of: KDM6A function deficiency, inactivation of KDM6A, and absence of KDM6A protein expression.
10 . The method of claim 9 , wherein the bladder tumor additionally has one or more of: p53 function deficiency, inactivation of p53, and no detectable p53 protein expression.
11 . The method of claim 9 , wherein cells of the bladder tumor comprise a p53 gene comprising a mutation.
12 . The method of claim 9 , wherein the method reduces growth of bladder cancer cells within a bladder, compared to growth of bladder cancer cells in a bladder in the absence of treatment.
13 . The method of claim 9 , further comprising determining that the individual's bladder cancer has one or more of: KDM6A function deficiency, inactivation of KDM6A, and absence of KDM6A protein expression.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 13, 2022
From: KOBATAKE, KOHEI
To: HIROSHIMA UNIVERSITY
Reel/Frame 059587/0244 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 13, 2022
From: HONDA, HIROAKI
To: TOKYO WOMEN'S MEDICAL UNIVERSITY
Reel/Frame 059587/0902 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 13, 2022
From: TOKYO WOMEN'S MEDICAL UNIVERSITY; HIROSHIMA UNIVERSITY
To: TOKYO WOMEN'S MEDICAL UNIVERSITY; HIROSHIMA UNIVERSITY; CHUGAI SEIYAKU KABUSHIKI KAISHA
Reel/Frame 059588/0608 →
Priority Claims (1)
JP 2019-078928
· Apr 17, 2019
· national
Continuity (1)
References Cited (400)
US 5126250A
· McDonough et al.
· 1992
[cited by applicant]
US 5216128A
· Novick et al.
· 1993
[cited by applicant]
US 5530101A
· Queen et al.
· 1996
[cited by applicant]
US 5621077A
· Novick et al.
· 1997
[cited by applicant]
US 5639455A
· Shimamura et al.
· 1997
[cited by applicant]
US 5670373A
· Kishimoto
· 1997
[cited by applicant]
US 5795965A
· Tsuchiya et al.
· 1998
[cited by applicant]
US 5817790A
· Tsuchiya et al.
· 1998
[cited by applicant]
US 5856135A
· Tsuchiya et al.
· 1999
[cited by applicant]
US 5888510A
· Kishimoto et al.
· 1999
[cited by applicant]
US 6074643A
· Barbera-Guillem
· 2000
[cited by applicant]
US 6121423A
· Tsuchiya et al.
· 2000
[cited by applicant]
US 6261560B1
· Tsujinaka et al.
· 2001
[cited by applicant]
US 6309636B1
· Do Couto
· 2001
[cited by applicant]
US 6552083B1
· Isobe et al.
· 2003
[cited by applicant]
US 6723319B1
· Ito et al.
· 2004
[cited by applicant]
US 8470316B2
· Yasunami
· 2013
[cited by applicant]
US 8562991B2
· Igawa et al.
· 2013
[cited by applicant]
US 8623355B2
· Okada et al.
· 2014
[cited by applicant]
US 8771686B2
· Ishida
· 2014
[cited by applicant]
US 8945558B2
· Kobara
· 2015
[cited by applicant]
US 9017677B2
· Mihara
· 2015
[cited by applicant]
US 9260516B2
· Nishimoto et al.
· 2016
[cited by applicant]
US 9539322B2
· Nishimura
· 2017
[cited by applicant]
US 9725514B2
· Takahashi et al.
· 2017
[cited by applicant]
US 20020119150A1
· Kirk et al.
· 2002
[cited by applicant]
US 20020187150A1
· Mihara et al.
· 2002
[cited by applicant]
US 20040018540A1
· Yamamura et al.
· 2004
[cited by applicant]
US 20050182007A1
· McSwiggen et al.
· 2005
[cited by applicant]
US 20060039902A1
· Young et al.
· 2006
[cited by applicant]
US 20060165696A1
· Okano et al.
· 2006
[cited by applicant]
US 20060193772A1
· Ochiai et al.
· 2006
[cited by applicant]
US 20060292147A1
· Yoshizaki et al.
· 2006
[cited by applicant]
US 20070036785A1
· Kishimoto et al.
· 2007
[cited by applicant]
US 20070134242A1
· Nishimoto et al.
· 2007
[cited by applicant]
US 20080081041A1
· Nemeth et al.
· 2008
[cited by applicant]
US 20090022719A1
· Mihara et al.
· 2009
[cited by applicant]
US 20090022726A1
· Zaki et al.
· 2009
[cited by applicant]
US 20090269335A1
· Nakashima et al.
· 2009
[cited by applicant]
US 20110111406A1
· Igawa et al.
· 2011
[cited by applicant]
US 20110245473A1
· Igawa et al.
· 2011
[cited by applicant]
US 20120183539A1
· Maeda
· 2012
[cited by applicant]
US 20120253016A1
· Igawa et al.
· 2012
[cited by applicant]
US 20130317203A1
· Igawa et al.
· 2013
[cited by applicant]
US 20160022812A1
· Mitsunaga et al.
· 2016
[cited by applicant]
US 20170121412A1
· Igawa et al.
· 2017
[cited by applicant]
US 20170362304A1
· Fukuda et al.
· 2017
[cited by applicant]
US 20180222986A1
· Maeda
· 2018
[cited by applicant]
US 20190085085A1
· Igawa et al.
· 2019
[cited by applicant]
US 20210017286A1
· Kakehi et al.
· 2021
[cited by applicant]
US 20210206862A1
· Igawa et al.
· 2021
[cited by applicant]
US 20220041741A1
· Igawa et al.
· 2022
[cited by applicant]
US 20220220210A1
· Takeshita et al.
· 2022
[cited by applicant]
US 20220306755A1
· Igawa et al.
· 2022
[cited by applicant]
US 20230159648A1
· Igawa et al.
· 2023
[cited by applicant]
US 20240010738A1
· Igawa et al.
· 2024
[cited by applicant]
US 20240150477A1
· Kakehi et al.
· 2024
[cited by applicant]
US 20240158518A1
· Ozawa et al.
· 2024
[cited by applicant]
US 20240301075A1
· Igawa et al.
· 2024
[cited by applicant]
US 20240417480A1
· Kakehi et al.
· 2024
[cited by applicant]
AR 068564
· 2009
[cited by applicant]
CA 1332367
· 1994
[cited by applicant]
CA 2203182
· 1996
[cited by applicant]
CA 2443294
· 2002
[cited by applicant]
CA 2523577
· 2004
[cited by applicant]
CA 2549467
· 2005
[cited by applicant]
CA 2560953
· 2005
[cited by applicant]
CA 2625773
· 2007
[cited by applicant]
CA 2626688
· 2007
[cited by applicant]
CA 2648644
· 2007
[cited by applicant]
CA 2700394
· 2009
[cited by applicant]
CA 2700498
· 2009
[cited by applicant]
CN 1164194A
· 1997
[cited by applicant]
CN 1297357A
· 2001
[cited by applicant]
CN 1694894A
· 2005
[cited by applicant]
CN 1849135A
· 2006
[cited by applicant]
CN 101849006
· 2010
[cited by applicant]
CN 102574918
· 2012
[cited by applicant]
CN 101370525B
· 2013
[cited by applicant]
CN 103476410
· 2013
[cited by applicant]
CN 103476793
· 2013
[cited by applicant]
CN 107224440
· 2017
[cited by applicant]
EP 0361902A
· 1990
[cited by applicant]
EP 0628639A
· 1994
[cited by applicant]
EP 0721783A1
· 1996
[cited by applicant]
EP 0783893A
· 1997
[cited by applicant]
EP 0791359A
· 1997
[cited by applicant]
EP 0811384A1
· 1997
[cited by applicant]
EP 0931544A2
· 1999
[cited by applicant]
EP 0983767A
· 2000
[cited by applicant]
EP 1004315A
· 2000
[cited by applicant]
EP 1074268A
· 2001
[cited by applicant]
EP 1108435A1
· 2001
[cited by applicant]
EP 1197210A1
· 2002
[cited by applicant]
EP 1334731A
· 2003
[cited by applicant]
EP 1374900A
· 2004
[cited by applicant]
EP 1562968A0
· 2005
[cited by applicant]
EP 1690550A
· 2006
[cited by applicant]
EP 1707215A
· 2006
[cited by applicant]
EP 1728801A
· 2006
[cited by applicant]
EP 1733740A
· 2006
[cited by applicant]
EP 1941907A
· 2008
[cited by applicant]
EP 1941908A
· 2008
[cited by applicant]
EP 1967207A
· 2008
[cited by applicant]
EP 1967209A
· 2008
[cited by applicant]
EP 1990060A
· 2008
[cited by applicant]
EP 2025346A1
· 2009
[cited by applicant]
EP 2123302A
· 2009
[cited by applicant]
EP 2174667A
· 2010
[cited by applicant]
EP 2194066A
· 2010
[cited by applicant]
EP 2196220A
· 2010
[cited by applicant]
EP 2202245A
· 2010
[cited by applicant]
EP 2206775A
· 2010
[cited by applicant]
EP 2275443A
· 2011
[cited by applicant]
EP 2305306A
· 2011
[cited by applicant]
EP 2330193A
· 2011
[cited by applicant]
EP 2578233A
· 2013
[cited by applicant]
EP 2639305A
· 2013
[cited by applicant]
EP 3009518A1
· 2016
[cited by applicant]
EP 3483283A1
· 2019
[cited by applicant]
ES 2276525T
· 2007
[cited by applicant]
FR 2694767A
· 1994
[cited by applicant]
JP H02163096
· 1990
[cited by applicant]
JP H06505253A
· 1994
[cited by applicant]
JP H06237772A
· 1994
[cited by applicant]
JP H07046998A
· 1995
[cited by applicant]
JP H08208514A
· 1996
[cited by applicant]
JP H1189582A
· 1999
[cited by applicant]
JP H11180873A
· 1999
[cited by applicant]
JP 3345419B2
· 2002
[cited by applicant]
JP 2003525243A
· 2003
[cited by applicant]
JP 2004028926
· 2004
[cited by applicant]
JP 2005524606A
· 2005
[cited by applicant]
JP 2005281235A
· 2005
[cited by applicant]
JP 2006503001A
· 2006
[cited by applicant]
JP 2006512325A
· 2006
[cited by applicant]
JP 2006524685A
· 2006
[cited by applicant]
JP 2007528691A
· 2007
[cited by applicant]
JP 2008037875A
· 2008
[cited by applicant]
JP 2008037876A
· 2008
[cited by applicant]
JP 2008538931A
· 2008
[cited by applicant]
JP 2008297315A
· 2008
[cited by applicant]
JP 4468578B2
· 2010
[cited by applicant]
JP 2010527615A
· 2010
[cited by applicant]
JP 2012500020
· 2012
[cited by applicant]
JP 2013541594
· 2013
[cited by applicant]
JP 5530635B2
· 2014
[cited by applicant]
KR 20060010765
· 2006
[cited by applicant]
KR 20070035482
· 2007
[cited by applicant]
RU 2127117C1
· 1999
[cited by applicant]
RU 2147442
· 2000
[cited by applicant]
RU 2195960
· 2003
[cited by applicant]
RU 2430111
· 2011
[cited by applicant]
TW 2008038985A
· 2008
[cited by applicant]
TW 201021829
· 2010
[cited by applicant]
TW 201302219
· 2013
[cited by applicant]
WO WO9212729A1
· 1992
[cited by applicant]
WO WO9219759
· 1992
[cited by applicant]
WO WO9308817A1
· 1993
[cited by applicant]
WO WO9420488A1
· 1994
[cited by applicant]
WO WO9428159A1
· 1994
[cited by applicant]
WO WO9509873A1
· 1995
[cited by applicant]
WO WO96011020
· 1996
[cited by applicant]
WO WO9612503
· 1996
[cited by applicant]
WO WO9625174A1
· 1996
[cited by applicant]
WO WO9836061A2
· 1998
[cited by applicant]
WO WO9842377
· 1998
[cited by applicant]
WO WO9908707
· 1999
[cited by applicant]
WO WO9947170
· 1999
[cited by applicant]
WO WO9958572
· 1999
[cited by applicant]
WO WO9960013A2
· 1999
[cited by applicant]
WO WO0010607A1
· 2000
[cited by applicant]
WO WO0105394A1
· 2001
[cited by applicant]
WO WO0145678A2
· 2001
[cited by applicant]
WO WO0164214A2
· 2001
[cited by applicant]
WO WO0203492A1
· 2002
[cited by applicant]
WO WO0234292
· 2002
[cited by applicant]
WO WO02080969
· 2002
[cited by applicant]
WO WO03048205A2
· 2003
[cited by applicant]
WO WO03105861A1
· 2003
[cited by applicant]
WO WO2004007701A1
· 2004
[cited by applicant]
WO WO2004039826A1
· 2004
[cited by applicant]
WO WO2004045507A2
· 2004
[cited by applicant]
WO WO2004045512A2
· 2004
[cited by applicant]
WO WO2004045520A2
· 2004
[cited by applicant]
WO WO2004071404A2
· 2004
[cited by applicant]
WO WO2004073741A1
· 2004
[cited by applicant]
WO WO2004096273
· 2004
[cited by applicant]
WO WO2005028514A1
· 2005
[cited by applicant]
WO WO2005037315
· 2005
[cited by applicant]
WO WO2005044848A1
· 2005
[cited by applicant]
WO WO2005061000
· 2005
[cited by applicant]
WO WO2005080429
· 2005
[cited by applicant]
WO WO2005090405
· 2005
[cited by applicant]
WO WO2005107800A1
· 2005
[cited by applicant]
WO WO2006009092A1
· 2006
[cited by applicant]
WO WO2006023144
· 2006
[cited by applicant]
WO WO2006070286
· 2006
[cited by applicant]
WO WO2006072954A2
· 2006
[cited by applicant]
WO WO2006119115
· 2006
[cited by applicant]
WO WO2007024715A2
· 2007
[cited by applicant]
WO WO2007043641
· 2007
[cited by applicant]
WO WO2007046489
· 2007
[cited by applicant]
WO WO2007058194
· 2007
[cited by applicant]
WO WO2007061029
· 2007
[cited by applicant]
WO WO2007067976A2
· 2007
[cited by applicant]
WO WO2007074880
· 2007
[cited by applicant]
WO WO2007076927A1
· 2007
[cited by applicant]
WO WO2007086490
· 2007
[cited by applicant]
WO WO2007114319
· 2007
[cited by applicant]
WO WO2007116962
· 2007
[cited by applicant]
WO WO2007137984
· 2007
[cited by applicant]
WO WO2007143168
· 2007
[cited by applicant]
WO WO2008020079
· 2008
[cited by applicant]
WO WO2008090901
· 2008
[cited by applicant]
WO WO2008144763A2
· 2008
[cited by applicant]
WO WO2009010539
· 2009
[cited by applicant]
WO WO2009014263
· 2009
[cited by applicant]
WO WO2009041613
· 2009
[cited by applicant]
WO WO2009041621
· 2009
[cited by applicant]
WO WO2009041643
· 2009
[cited by applicant]
WO WO2009044774
· 2009
[cited by applicant]
WO WO2009125825
· 2009
[cited by applicant]
WO WO2009148148
· 2009
[cited by applicant]
WO WO2010021697
· 2010
[cited by applicant]
WO WO2010035769
· 2010
[cited by applicant]
WO WO2010065078
· 2010
[cited by applicant]
WO WO2010107108
· 2010
[cited by applicant]
WO WO2010115868
· 2010
[cited by applicant]
WO WO2011013786
· 2011
[cited by applicant]
WO WO2011149046
· 2011
[cited by applicant]
WO WO2011149051
· 2011
[cited by applicant]
WO WO2011154139A2
· 2011
[cited by applicant]
WO WO2012063875
· 2012
[cited by applicant]
WO WO2012064627
· 2012
[cited by applicant]
WO WO2012094703
· 2012
[cited by applicant]
WO WO2012118750
· 2012
[cited by applicant]
WO WO2014200018
· 2014
[cited by applicant]
WO WO2016027859
· 2016
[cited by applicant]
WO WO2016104777
· 2016
[cited by applicant]
WO WO2016104777A1
· 2016
[cited by examiner]
WO WO2016136933
· 2016
[cited by applicant]
WO WO2016186154
· 2016
[cited by applicant]
WO WO2018008750A1
· 2018
[cited by applicant]
WO WO2018203545
· 2018
[cited by applicant]
WO WO2019078344A1
· 2019
[cited by applicant]
WO WO2019151418A1
· 2019
[cited by applicant]
WO WO2020202839
· 2020
[cited by applicant]
WO WO2022191306
· 2022
[cited by applicant]
WO WO2023095852A1
· 2023
[cited by applicant]
WO WO2023140269A1
· 2023
[cited by applicant]
Kovaleva “Tumor Associated Macrophages in Kidney Cancer”. Analytical Cellular Pathology vol. 2016, Article ID 9307549, 6 pages. (Year: 2016).
[cited by examiner]
Chen, Miao-Fen et al. “IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer.” PloS one vol. 8,4 e61901. Apr. 30, 2013, doi:10.1371/journal.pone.0061901 (Year: 2013).
[cited by examiner]
O'Connor, Tracy et al. “CCL2-CCR2 Signaling in Disease Pathogenesis.” Endocrine, metabolic & immune disorders drug targets vol. 15,2 (2015): 105-18. (Year: 2015).
[cited by examiner]
Kobatake, Kohei; Ikeda, Ken ichiro; Nakata, Yuichiro; Sera, Yasuyuki; Hayashi, Tetsutaro; et al. Cancer Science, suppl. 1109: 167. Wiley. (Jan. 2018). Abstract. (Year: 2018).
[cited by examiner]
Park. “H3K27 Demethylase JMJD3 Employs the NF-κB and BMP Signaling Pathways to Modulate the Tumor Microenvironment and Promote Melanoma Progression and Metastasis”. Cancer Res (2016) 76 (1): 161-170. https://doi.org/10.…
[cited by examiner]
Ntziachristos, P., Tsirigos, A., Welstead, G. et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514, 513-517 (2014). (Year: 2014).
[cited by examiner]
Zehui. “Different expression patterns of histone H3K27 demethylases in renal cell carcinoma and bladder cancer”. Cancer Biomarkers, vol. 18, No. 2, pp. 125-131, 2017. Abstract. (Year: 2017).
[cited by examiner]
Ando et al., “Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer,” PLOS One, Jul. 1, 20140, 9(7):e102436. doi: 10.1371/journal.pone.0102436. eCollection 2014.
[cited by applicant]
“Interleukin 6-wikipedia”, Feb. 22, 2019, XP055598802, Retrieved from the Internet Jun. 24, 2019: URL:https://protect-us.mimecast.com/s/6UxpCmZ28nsApl8JnGhTki?domain=en.wikipedia.org.
[cited by applicant]
Armour et al., “Recombinant human IgG molecules lacking Fcy receptor I binding and monocyte triggering activities,” Eur J Immunol, Aug. 1999, 29(8):2613-2624.
[cited by applicant]
Srivastava et al., “Potassium Channel IGR.4.1 as an Immune Target in Multiple Sclerosis,” N Engl J Med, Jul. 12, 2012, 367(2):115-123. doi:10.1056/NEJMoa1110740.
[cited by applicant]
U.S. Appl. No. 18/820,608, Kakehi et al., filed Aug. 30, 2024.
[cited by applicant]
U.S. Appl. No. 18/956,095, Igawa et al., filed Nov. 22, 2024.
[cited by applicant]
U.S. Appl. No. 18/975,370, Igawa et al., filed Dec. 10, 2024.
[cited by applicant]
U.S. Appl. No. 18/975,370, Igawa et al., Dec. 10, 2024.
[cited by applicant]
Airoldi et al., “IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions,” PLoS One, Jul. 1, 2009, 4(7):e6119, 11 pages.
[cited by applicant]
Akira et al., “The evidence for interleukin-6 as an autocrine growth factor in malignancy,” Semin Cancer Biol, Feb. 1992, 3(1):17-26.
[cited by applicant]
Alvarez et al., “Tumor necrosis factor-α exerts interleukin-6-dependent and -independent effects on cultured skeletal muscle cells,” Biochim Biophys Acta, Jan. 30, 2002, 1542(1-3):66-72.
[cited by applicant]
Ano et al., “Transcription Factors GATA-3 and RORγt are Important for Determining the Phenotype of Allergic Airway Inflammation in a Murine Model of Asthma,” J Immunol, Feb. 1, 2013, 190(3):1056-1065. doi: 10.4049/jimmu…
[cited by applicant]
Armstrong et al., “Melanoma-Derived Interleukin 6 Inhibits In Vivo Melanoma Growth,” J Invest Dermatol, Mar. 1994, 102(3):278-284.
[cited by applicant]
Ashizawa et al., “Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor,” Gastric Cancer, May 2005, 8(2):124-131.
[cited by applicant]
Barton-Davis et al., “Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle formation,” Proc Natl Acad Sci USA, Dec. 22, 1998, 95(26):15603- 15607.
[cited by applicant]
Beck et al., “Brief Report: Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody,” N Engl J Med, Mar. 3, 1994, 330(9):602-605.
[cited by applicant]
Becker, “Molecular Immunological Approaches to Biotherapy of Human Cancers—A Review. Hypothesis and Implications,” Anticancer Res. Mar.-Apr. 2006, 26(2A):1113-1134.
[cited by applicant]
Bellomo, “The Cytokine Network in the Critically Ill,” Anaesth Intensive Care, Aug. 1992, 20(3):288-302.
[cited by applicant]
Benda et al., “Interleukin-6 in islet xenograft rejection.” Transpl Int. Mar. 2001, 14(2):63-71.
[cited by applicant]
Berger et al., “Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lunch metastasis,” Proc Natl Acad Sci USA, Feb. 16, 2010, 107(7):2995-3000. doi: 10.1073/pnas.10001011…
[cited by applicant]
Bertagnolli et al., “IL-4-Supported Induction of Cytolytic T Lymphocytes Requires IL-2 and IL-6.” Cell Immunol, Apr. 1, 1991, 133(2):327-341.
[cited by applicant]
Besse et al., “Phase 2 Study of Frontline Bortezomib in Patients with Advanced Non-Small Cell Lung Cancer,” Lung Cancer, Apr. 2012, 76(1):78-83. doi: 10.1016/j.lungcan.2011.09.006. Epub Dec. 18, 2011.
[cited by applicant]
Biswas et al., “Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection,” Exp Eye Res, Jan. 2006, 82(1):46-54. Epub Jul. 11, 2005.
[cited by applicant]
Bogdanovich et al., “Functional improvement of dystrophic muscle by myostatin blockade.” Nature, Nov. 28, 2002, 420(6914):418-421.
[cited by applicant]
Bond et al., “Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB,” Febs Lett, Sep. 11, 1998, 435(1):29-34.
[cited by applicant]
Borg et al., “15-Deoxyspergualin inhibits interleukin 6 production in in vitro stimulated human lymphocytes,” Transpl Immunol, Jun. 1996, 4(2):133-143.
[cited by applicant]
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Res, Apr. 2000, 10(4):398-400.
[cited by applicant]
Bork et al., “Go hunting in sequence databases but watch out for the traps,” Trends Genet, Oct. 1996, 12(10):425-427.
[cited by applicant]
Borsellino et al., “Blocking Signaling through the Gp130 Receptor Chain by Interleukin-6 and Oncostatin M Inhibits PC-3 Cell Growth and Sensitizes the Tumor Cells to Etoposide and Cisplatin-Mediated Cytotoxicity,” Cance…
[cited by applicant]
Brenner, “Errors in genome annotation,” Trends Genet, Apr. 1999, 15(4):132-133.
[cited by applicant]
Bromberg, “The IL-6/Jak/Stat3 Pathway: Targeting Metastatic Breast Cancer Research Update,” posted on 2/29/2009, retrieved on Mar. 10, 2013, retrieved from URL <http://www.mountainsofhopefoundation.org/foundation-news/6…
[cited by applicant]
Burska et al., “Gene expression analysis in RA: towards personalized medicine,” Pharmacogenomics J, Apr. 2014. 14(2):93-106.
[cited by applicant]
Cabillic et al., “Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk,” Clin Exp Immunol, Dec. 2006. 146(3):518-523.
[cited by applicant]
Campbell et al., “Essential Role for Interferon-γ and Interleukin-6 in autoimmune Insulin-dependent Diabetes in NOD/Wehi Mice,” J Clin Invest, Feb. 1991, 87(2):739-742.
[cited by applicant]
Campbell et al., “Evidence for IL-6 Production by and Effects on the Pancreatic β-Cell,” J Immunol, Aug. 15, 1989, 143(4):1188-1191.
[cited by applicant]
Campo et al., “Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B cell lymphoma,” Cytokine, Sep. 7, 2005, 31(5):368-374.
[cited by applicant]
Campochiaro, “Retinal and Choroidal Neovascularization,” J Cell Physiol, Sep. 2000, 184(3):301-310.
[cited by applicant]
Capelo et al., “Visceral adiposity is associated with cytokines and decrease in lung function in women with persistent asthma,” Rev Port Pneumol, Sep.-Oct. 2016 22(5):255-261. doi: 10.1016/j.rppnen.2016.02.005. Epub Mar…
[cited by applicant]
Ceyhan et al., “Neural invasion in pancreatic cancer: A mutual tropism between neurons and cancer cells,” Biochem Biophys Res Commun, Sep. 26, 2008, 374(3):442-447. Epub Jul. 18, 2008.
[cited by applicant]
Charge et al., “Cellular and Molecular Regulation of Muscle Regeneration,” Physiol Rev, Jan. 2004, 84(1):209-238.
[cited by applicant]
Cheong et al., “Peritoneal healing and adhesion formation/reformation,” Hum Reprod Update, Nov.-Dec. 2001, 7(6):556-566.
[cited by applicant]
Choi et al., “IL-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo,” Transpl Immunol, Jun.-Jul. 2004, 13(1):43-53.
[cited by applicant]
Chu et al., “Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma,” Allergy Asthma Clin Immunol, Apr. 2, 2015, 11(1):14. doi: 10.1186/s13223-015-0081-1. eCollection 2015.
[cited by applicant]
Chung et al., “Serum Interleukin-6 Levels Reflect the Disease Status of Colorectal Cancer,” J Surg Oncol, Aug. 2003, 83(4):222-226.
[cited by applicant]
Chuntharapai et al., “Generation of Monoclonal Antibodies to Chemokine Receptors,” Methods Enzymol, 1997, 288:15-27.
[cited by applicant]
ClinicalTrials.gov [online], “A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma,” NCT02794519, first posted Jun. 9, 2016, retrieved on Jul. 8, 2021, retrieved at URL …
[cited by applicant]
Culig et al., “Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth,” Mol Cell Endocrinol, Nov. 29, 2002, 197(1-2):231-238.
[cited by applicant]
Dangott et al., “Dietary Creatine Monohydrate Supplementation Increases Satellite Cell Mitotic Activity During Compensatory Hypertrophy,” Int J Sports Med, Jan. 2000, 21(1):13-16.
[cited by applicant]
Darr et al., “Hindlimb suspension suppresses muscle growth and satellite cell proliferation,” J Appl Physiol, Nov. 1989, 67(5):1827-1834.
[cited by applicant]
Davies et al., “The HGF/SF Antagonist NK4 Reverses Fibroblast- and HGF-Induced Prostate Tumor Growth and Angiogenesis In Vivo,” Int J Cancer, Sep. 1, 2003, 106(3):348-354.
[cited by applicant]
De Vita et al., “Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer,” Oncol Rep, May-Jun. 1998, 5(3):649-652.
[cited by applicant]
Demir et al., “Nerve-Cancer Interactions in the Stromal Biology of Pancreatic Cancer,” Frontiers in Physiology, 2012, 3(97):1-22.
[cited by applicant]
Ding et al., “The change of plasma interleukin-6 level and cardiac protective effect of monoclonal antibody to IL-6 during myocardial infarction reperfusion,” Chinese Journal of Cardiology, 1999, 27(1):29-32 (with Engli…
[cited by applicant]
Doerks et al., “Protein annotation: detective work for function prediction,” Trends Genet, Jun. 1998, 14(6):248-250.
[cited by applicant]
Doganci et al., “The IL-6R α chain controls lung CD4
[cited by applicant]
Duluc et al., “Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells,” Blood, Dec. 15, 2007, 110(13):4319-4330. Epub Sep. 11, 2007.
[cited by applicant]
Ebos et al., “Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis,” Cancer Cell, Mar. 3, 2009, 15(3):232-239. doi: 10.1016/j.ccr.2009.01.021.
[cited by applicant]
Eder et al., “Targeting the androgen receptor in hormone-refractory prostate cancer—new concepts,” Future Oncol, Feb. 2005, 1(1):93-101.
[cited by applicant]
Esty et al., “Abstract No. AB109: 346 Anti-IL-6 treatment in two pediatric patients with severe persistent asthma with the IL4R
[cited by applicant]
Feaver et al., “Abstract No. 439: The Anti-IL-6 Antibody Sirukumab Inhibits Vascular Inflammation in a Human Surrogate Model of Atherosclerosis,” Presented at 2014 ACR/ARHP Annual Meeting, Boston, MA, Nov. 14-19, 2014; …
[cited by applicant]
Finkel et al., “Negative Inotropic Effects of Cytokines on the Heart Mediated by Nitric Oxide,” Science, Jul. 17, 1992, 257(5068):387-389.
[cited by applicant]
Fisniku et al., “Protective Effects of PG490-88 on Chronic Allograft Rejection by Changing Intragraft Gene Expression Profiles,” Transplant Proc, May 2005, 37(4):1962-1964.
[cited by applicant]
Ford et al., “Evidence that Production of Interleukin 6 within the Rejecting Allograft Coincides with Cytotoxic T Lymphocyte Development,” Transplantation, Mar. 1991, 51(3):656-661.
[cited by applicant]
Fraunberger et al., “Cytokine and Cytokine-Receptor Profiles After Liver and Heart Transplantation,” Transplant Proc, Jun. 1995, 27(3):2023-2027.
[cited by applicant]
Fredj et al., “Role of Interleukin-6 in Cardiomyocyte/Cardiac Fibroblast Interactions During Myocyte Hypertrophy and Fibroblast Proliferation,” J Cell Physiol, Aug. 2005, 204(2):428-436.
[cited by applicant]
Fuchs et al., “Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction,” FASEB J, Nov. 2003, 17(14):2118-2120. Epub Sep. 4, 2003.
[cited by applicant]
Fujita et al., “Anti-Interleukin-6 Receptor Antibody Prevents Muscle Atrophy in Colon-26 Adenocarcinoma-Bearing Mice with Modulation of Lysosomal and ATP-Ubiquitin-Dependent Proteolytic Pathways,” Int J Cancer, Nov. 27,…
[cited by applicant]
Fujiwara et al., “1. Control of Tumor immunity by B cells and Th2 cytokines,” Annual Review Meneki, 1999, pp. 257-269 (with English translation).
[cited by applicant]
Furukawa et al., “Cytokine Gene Expression During the Development of Graft Coronary Artery Disease in Mice,” Jpn Circ J, Oct. 1999, 63(10):775-782.
[cited by applicant]
Gao et al., “Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas,” J Clin Invest, Dec. 2007, 117(12):3846-3856.
[cited by applicant]
Garry et al., “Myogenic stem cell function is impaired in mice lacking the forkhead/winged helix protein MNF,” Proc Natl Acad Sci USA, May 9, 2000, 97(10):5416-5421.
[cited by applicant]
Garry et al., “Persistent Expression of MNF Identifies Myogenic Stem Cells in Postnatal Muscles,” Dev Biol, Aug. 15, 1997, 188(2):280-294.
[cited by applicant]
Ghosh et al., “Missing Pieces in the NF-κB Puzzle,” Cell, Apr. 2002, vol. 109, Suppl:S81-S96.
[cited by applicant]
Giugliano et al., “Verapamil inhibits interleukin-6 and vascular endothelial growth factor production in primary cultures of keloid fibroblasts,” Br J Plast Surg, Dec. 2003, 56(8):804-809.
[cited by applicant]
Greenberg et al., “Interleukin 6 Reduces Lipoprotein Lipase Activity in Adipose Tissue of Mice in Vivo and in 3T3-L1 Adipocytes: A Possible Role for Interleukin 6 in Cancer Cachexia,” Cancer Res, Aug. 1, 1992, 52(15):41…
[cited by applicant]
Greten et al., “IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer,” Cell, Aug. 6, 2004, 118(3):285-296.
[cited by applicant]
Grossniklaus et al., “Perspective—Choroidal Neovascularization,” Am J Ophthalmol, Mar. 2004, 137(3):496-503.
[cited by applicant]
Guice et al., “Anti-Tumor Necrosis Factor Antibody Augments Edema Formation in Caerulein-Induced Acute Pancreatitis,” J Surg Res, Dec. 1991, 51(6):495-499.
[cited by applicant]
Guillen et al., “Cytokine signaling during myocardial infarction: sequential appearance of IL-1β and IL-6,” Am J Physiol, Aug. 1995, 269(2 Pt 2):R229-R235.
[cited by applicant]
Gwechenberger et al., “Cardiac Myocytes Produce Interleukin-6 in Culture and in Viable Border Zone of Reperfused Infarctions,” Circulation, Feb. 2, 1999, 99(4):546-551.
[cited by applicant]
Habara et al., “The biological effects of antiadhesion agents on activated RAW264.7 macrophages,” J Biomed Mater Res, Sep. 15, 2002, 61(4):628-633.
[cited by applicant]
Hanahan et al., “Hallmarks of Cancer: The Next Generation,” Cell, Mar. 4, 2011, 144(5):646-674. doi: 10.1016/j.cell.2011.02.013.
[cited by applicant]
Hashizume et al., “IL-6 plays an essential role in neutrophilia under inflammation,” Cytokine, Apr. 2011, 54(1):92-99. doi: 10.1016/j.cyto.2011.01.007. Epub Feb. 2, 2011.
[cited by applicant]
Hashizume et al., “Various actions of IL-6—Significance of IL-6 in autoimmune and inflammatory diseases,” Folia Pharmacol Jpn, 2014, 144(4):172-177 (with English translation).
[cited by applicant]
Hatzi et al., “N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth,” Oncogene, May 16, 2002, 21(22):3552-3561.
[cited by applicant]
Hirai et al., “Perineural Invasion in Pancreatic Cancer,” Pancreas, Jan. 2002, 24(1):15-25.
[cited by applicant]
Hirota et al., “Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice,” Proc Natl Acad Sci USA, May 23, 1995, 92(11):4862-4866.
[cited by applicant]
Hirota et al., “Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress,” Cell, Apr. 16, 1999, 97(2):189-198.
[cited by applicant]
Hocking et al., “Mechanisms of Pulmonary Edema Induced by Tumor Necrosis Factor-α,” Circ Res, Jul. 1990, 67(1):68-77.
[cited by applicant]
Hoffmann et al., “Inhibitory effects of verapamil isomers on the proliferation of choroidal endothelial cells,” Graefes Arch Clin Exp Ophthalmol, Mar. 2006, 244(3):376-381. Epub Aug. 9, 2005.
[cited by applicant]
Holmdahl, “The Role of Fibrinolysis in Adhesion Formation,” Eur J Surg Suppl, 1997, (Supp 577):24-31.
[cited by applicant]
Hong et al., “Interleukin-6 and its receptor in cancer: implications for translational therapeutics,” Cancer, Nov. 1, 2007, 110(9):1911-1928.
[cited by applicant]
Horinaga et al., “Clinical and Pathologic Significance of Activation of Signal Transducer and Activator of Transcription 3 in Prostate Cancer,” Urology, Sep. 2005, 66(3):671-675.
[cited by applicant]
Hornick et al., “Chapter 5 Chronic Rejection in the Heart,” Methods Mol Biol, 2006, 333:131-44.
[cited by applicant]
Huang et al., “Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro,” Cancer Sci, Dec. 2006, 97(12):1417-1423. Epub Oct. 19, 2006.
[cited by applicant]
Huang et al., “Inhibitory effect of AG490 on invasion and metastasis of human pancreatic cancer cells in vitro,” Clin J Oncol, Dec. 2006, 28(12):890-893 (with English abstract).
[cited by applicant]